Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Why do you wish CCEL to fail ?
BURN CCEL BURN ! Keep Burning that green !
So should I STAY TUNED ?
Juices is cash and CHOI SAID CCEL MANAGEMENT IS BLOWING THROUGH IT! ROTFLMFAO
Don't need juices when you have cash .
CCELS RUNNING OUT OF JUICES!
Living off their cash pile is better then living off juice's . CCEL $2.30 the company running on it own juice 0.014 after a 1 for 100 RS , kinda pathetic don't you think ? I mean a 1 for 100 RS and you wind up at 0.014 with the captain jumping ship .
CCEL CAN ONLY LIVE OF THERE CASH PILE FOR SO LONG. BYE BYE CCEL IF CHOI DOESNT GET HIS CHANCE TO CHANGE MANAGEMENT.BYE BYE CCEL
CCEL over $2.00 its competitor the 4th largest parking garage for cords under 2 cents after a 1 for 100 RS
"Based on only two quarters of results, the Company's performance appears to be deteriorating ."
"We take issue with the board's appointment of the Portnoy brothers as co-CEOs. During last year's proxy campaign, the Portnoys didn't reveal that, in addition to serving on the board, they also intended to fill the CEO position themselves...We believe the appointment of the Portnoy brothers as co-CEOs was a veiled and substantial overreach of power, which we don't think many investors signed up for."
Leading Independent Proxy Advisory Firm Glass, Lewis & Co. Recommends Stockholders Vote to Elect All of Mr. Choi's Director N...
Date :
07/05/2012 @ 8:30AM
Source :
PR Newswire
Stock :
Cryo-Cell Intl (CCEL)
Quote :
2.35 0.1 (4.44%) @ 3:57PM
<a href="http://us-ads.openx.net/w/1.0/rc?cs=4f5941efcdffb&cb=INSERT_RANDOM_NUMBER_HERE" ><img src="http://us-ads.openx.net/w/1.0/ai?auid=160609&cs=4f5941efcdffb&cb=INSERT_RANDOM_NUMBER_HERE" border="0" alt=""></a>
Leading Independent Proxy Advisory Firm Glass, Lewis & Co. Recommends Stockholders Vote to Elect All of Mr. Choi's Director N...
Print
Alert
Cryo-Cell Intl (OTCBB:CCEL)
Intraday Stock Chart
Today : Thursday 5 July 2012
Ki Yong Choi, the largest stockholder of Cryo-Cell International, Inc. (OTCBB: CCEL) with approximately 19.6% of the company's outstanding shares, today announced that Glass, Lewis & Co., LLC ("Glass Lewis"), a leading proxy advisory firm, issued a report on July 2, 2012 recommending that Cryo-Cell stockholders vote on the GOLD proxy card for ALL six of Mr. Choi's Board nominees.
In response to the Glass Lewis report, Mr. Choi issued the following statement:
"We are extremely pleased that independent proxy advisory firms Glass Lewis, ISS and Egan-Jones support change at Cryo-Cell. We greatly appreciate the support from the independent proxy advisory firms, and from the stockholders who have already voted for my Board nominees on the GOLD proxy card," stated Ki Yong Choi. "If you have not voted yet, it is still not too late to vote or change your vote to make a difference. We are very committed to looking out for the best interests of ALL stockholders."
The independent Glass Lewis report sums up the problems at Cryo-Cell(1):
"In sum, we believe the current board and the Portnoy brothers specifically acted disingenuously by taking over the Company as co-CEOs after winning election to the board in last year's proxy contest. In our view, this has left them in over their heads, unqualified to be managing a life sciences company such as Cryo-Cell. Further, we believe the board has failed to protect shareholder interests by not conducting an adequate search for a qualified CEO, not seeking to nominate an independent chairman or lead director and approving compensation and share buy-back programs that do not appear to be in the best interests of shareholders."
"Under normal circumstances, we would be inclined to grant a new board more than 10 months to attempt to engineer improvements. But given the way in which the Portnoys became co-CEOs, their actions during this year's proxy contest and the manner in which they have managed Cryo-Cell thus far, we don't believe shareholders can afford to wait another year to re-evaluate the situation."
Glass Lewis highlights incorrect allegations made by the current Board and the co-CEOs:
"In a sign that the current board and co-CEOs may be acting disingenuously with shareholders, we note that the Company made a number of allegations in its June 25, 2012, proxy materials that it three days later publicly admitted were incorrect."
Glass Lewis believes the company's performance appears to be deteriorating under the Portnoy brothers' direction:
"Operationally, the new board and management have struggled to produce tangible results based on the two quarters reported thus far. In the first six months of the current board's tenure, revenues declined 5% and net earnings turned negative compared to the year-ago period."
"Based on only two quarters of results, the Company's performance appears to be deteriorating."
Glass Lewis believes the board's appointment of the Portnoy brothers as co-CEOs was an overreach of power:
"We take issue with the board's appointment of the Portnoy brothers as co-CEOs. During last year's proxy campaign, the Portnoys didn't reveal that, in addition to serving on the board, they also intended to fill the CEO position themselves...We believe the appointment of the Portnoy brothers as co-CEOs was a veiled and substantial overreach of power, which we don't think many investors signed up for."
ALL THREE INDEPENDENT PROXY ADVISORY FIRMS SUPPORT CHANGE AT CRYO-CELL
WHO IS SUPPORTING THE PORTNOYS?
While Director nominees put forward by Mr. Choi have now received support from each of the INDEPENDENT proxy advisory firms, it seems the only public support the Portnoy brothers have received has been from the COO of Saneron CCEL. This, however, is an entangled relationship that includes Cryo-Cell holding a 34%(2) ownership interest in Saneron CCEL. It certainly does not seem that the current Board and co-CEOs can muster any independent validation of their actions.
VOTE THE GOLD PROXY CARD TO MAKE A DIFFERENCE IN CRYO-CELL'S FUTURE
Stockholders are reminded that their vote is important, no matter how many shares they own. It is still not too late to vote or change your vote to make a difference.
Ki Yong Choi urges all stockholders to heed Glass Lewis & Co.'s recommendation for change on the Board of Cryo-Cell – it is important that Cryo-Cell stockholders return the GOLD proxy card and vote in favor of change in the boardroom. Cryo-Cell stockholders SHOULD NOT RETURN THE WHITE PROXY CARD or any other proxy card furnished to you on behalf of Cryo-Cell.
If any Cryo-Cell stockholder has already returned a proxy card, you have every right to change your vote by signing and returning a later-dated GOLD proxy card.
Investor Contact: Alliance Advisors LLC. Call Toll Free: (877) 777-2338; Banks and Brokers Call Collect: (973) 873-7700.
(1) Permission to use quotations was neither sought nor obtained.
(2) Cryo-Cell Form 10-K for the fiscal year ended November 30, 2011(page 11) - The Company owns an approximate 34% and 35% interest in Saneron CCEL Therapeutics, Inc. ("Saneron") as of November 30, 2011 and 2010, respectively.
SOURCE Ki Yong Choi
"Since August 2011, the date the Portnoy-led management team began running the company, aggregate and year-over-year quarterly revenues have declined, SG&A expenses have increased and total operating cash flow and normalized EBIT has decreased…"
Dont SEll Yet Choi the Vote isn't over Yet!
Nothing, is my guess.
So what is CCEL up to ! LMAO
THE MATH IS CORRECT.
(2,186,568/11,853,227) * 100 = 18.45%
(2,186,568/11,180,458) * 100 = 19.56%
HEY CCEL DO THE MATH ! As a result of a reduction in the number of the Issuer’s shares of Common Stock outstanding, the percentage ownership of the Reporting Persons’ Common Stock in the Issuer increased from 18.4% to 19.6%. On April 16, 2012 the Issuer reported 11,853,227 shares outstanding as of April 13, 2012. On June 19, 2012, the Issuer reported 11,180,458 shares outstanding as of June 18, 2012.
HEY CCEL DO THE MATH ! As a result of a reduction in the number of the Issuer’s shares of Common Stock outstanding, the percentage ownership of the Reporting Persons’ Common Stock in the Issuer increased from 18.4% to 19.6%. On April 16, 2012 the Issuer reported 11,853,227 shares outstanding as of April 13, 2012. On June 19, 2012, the Issuer reported 11,180,458 shares outstanding as of June 18, 2012.
PORTNOY LIES IN A FILING NO WAY ! Letter from the Chairman
1)
“Previously ousted Cryo-Cell Board member Ki Yong Choi and his brother-in-law are waging a proxy fight for control of your company. Both were voted out by shareholders in August 2011 as a result of frustration with the Board’s poor performance and a desire for a new business strategy.”
Mr. Choi and his brother-in-law were not voted out by shareholders in August 2011 as a result of frustration with the Board’s poor performance and a desire for a new business strategy. Rather, Mr. Choi and Mr. Cho, each of whom was a member of the Company’s Board of Directors until August 2011, were not re-nominated by the Company to serve as directors for the 2011 annual meeting after Mr. Choi submitted his own slate of nominees. Stockholders did not vote for or against Mr. Choi or his brother-in-law in the 2011 annual meeting election.
What are Choi’s Intentions?
2)
“On August 22, 2011, Mr. Choi submitted a 13D filing that stated his intention to amend the existing Cryo-Cell bylaws to enable any shareholder controlling at least 15% percent of the stock to remove any and all Board members without cause. Mr. Choi was well aware that his proposed change would apply only to him. Had he been successful, the net result would have enabled him to dismiss any Board members who did not support his viewpoint. This is in direct violation of Delaware law.”
On August 22, 2011, Mr. Choi did submit a 13D in which he proposed the following:
“the Board shall vote as directors to amend the bylaws of the Company to allow a stockholder holding fifteen percent (15%) or more of the outstanding capital stock of the Company to call a special election of stockholders for the election of directors and to allow removal of any or all directors without cause.”
The Company did not enact Mr. Choi’s proposed Bylaw amendment.
What are Choi’s Intentions?
3)
“On August 22, 2011, Mr. Choi submitted a 13D filing that stated his intention to amend the existing Cryo-Cell bylaws to enable any shareholder controlling at least 15% percent of the stock to remove any and all Board members without cause. Mr. Choi was well aware that his proposed change would apply only to him. Had he been successful, the net result would have enabled him to dismiss any Board members who did not support his viewpoint. This is in direct violation of Delaware law.”
The proposed bylaw amendment to allow a stockholder holding fifteen percent (15%) or more of the outstanding capital stock of the Company to call a special election of stockholders for the election of directors is not a violation of Delaware law. The proposed bylaw amendment to allow removal of directors without cause is not a violation of Delaware law.
What are Choi’s Intentions
4)
“ In his final days as a Cryo-Cell Board member, Mr. Choi voted to a wire transfer of $2.5 million into a trust for the then-current Board chairman.”
Mr. Choi voted to place $2.5 million in escrow to cover potential claims of Company officers which officers would become entitled to, subject to satisfaction of provisions in their employment agreements, upon the occurrence of a change of control of the Company.
Item 9.01.
Financial Statements and Exhibits.
(a)
Financial Statements of Businesses Acquired.
Not Applicable.
(b)
Pro Forma Financial Information
Not Applicable.
(c)
Shell Company Transactions
Not Applicable.
(d)
Exhibits.
Not Applicable.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
CRYO-CELL International, Inc.
DATE: June 28, 2012
By:
/s/ David I. Portnoy
David I. Portnoy
Co-Chief Executive Officer
WOW another Proxy! VOTE THE GOLD PROXY TODAY TO MAKE A DIFFERENCE IN CRYO-CELL'S FUTURE
Time is short. No matter how many or how few shares you own, it is important that you vote the GOLD proxy card today and vote in favor of electing us to represent you in the board room. Electronic voting is available to you. It’s fast and cost free. Please refer to the enclosed materials on how to vote your shares today. You SHOULD NOT RETURN THE WHITE PROXY CARD or any other proxy card furnished to you on behalf of Cryo-Cell. If you have already returned the WHITE proxy card, it is not too late to change your vote. By voting the enclosed GOLD proxy card, and voting for me and my director nominees and voting against approval Cryo-Cell’s 2012 Equity Incentive Plan, you can still help us change direction for Cryo-Cell and your vote will count.
As the largest stockholder of Cryo-Cell and a person who cares about Cryo-Cell and all of its stockholders, I vow to work tirelessly to get Cryo-Cell back on track. I thank you and look forward to your support.
Sincerely,
Ki Yong Choi Warns The Portnoys To Stop Deceiving Stockholders = Get them Choi. Things are heating up in CCEL land. VIVA LA MEXICO!Management is misrepresenting information about funds set aside for a potential severance payment for the former CEO. The co-CEO states that, when I was a Board member, I "voted to approve a wire transfer of $2.5 million into a trust" for the former CEO. The Board did approve money being set aside for potential severance payments to the former CEO and others resulting from employment terminations that occurred after last year's proxy contest. These funds are included on the company's balance sheet as restricted cash.
Management demonstrates a low threshold for achievement. In describing his interactions with Cryo-Cell de Mexico, the co-CEO states that their negotiation with Cryo-Cell's largest affiliate resulted in a loss of more than 60% of the revenue that it was owed. David Portnoy seems to call this a victory for the management team. This does not seem like something management should tout.
Co-CEOs marketing strategies show no evidence of progress. The co-CEOs describe sales and marketing alternatives to grow the business. The co-CEO seems to be touting these as victories in stating they are "Using Marketing Dollars Effectively." While these initiatives are certainly increasing expenses in Sales & Marketing, by a whopping 51%, revenue decreased 7% in the last fiscal quarter compared to the year before[1]. This is a considerable increase in Sales and Marketing spending – how long should stockholders wait for these efforts to bear fruit?
Choi himself said he has no desire to be CEO, but wants to do a search for a qualified individual. Do you know of anyone? Maybe Mercedes will come back!
BK ,are you sure you're looking at the right ticker symbol , this is CCEL not CBAI its used to be competitor that's 0.013 after a 1 for 100 RS ?
So when does CCEL CLOSE THEIR DOORS. WILL CHOI BE THE NEW CEO WHO COULD SAVE CCEL FROM BANKRUPTCY! JUST WONDERING
Yeah the 300 shares today and zero yesterday sure is keeping them alive LMFAO
Glad to see CCEL NEEDS TO DILUTE TO STAY ALIVE!
Really don't care about Richards and according to you he hasn't been paid maybe they're done paying him . I think you're the one whose been saying for the last year that there is NO volume in CCEL trading . We all know the results of excessive dilution as is in evidence in the 90% loss to CCEL's competitor to a point of 0.013 pps all after a 1 for 100 RS, now that's EXCESSIVE DILUTION . What did they use that dilution money for , pay bills ?
So no dilution for two days, look out CCEL MIGHT HAVE TO CLOSE THEIR DOORS. LOOKS LIKE MANAGEMENT STOPPED BUYING THEIR OWN STOCK. STAY TUNED, SO DID CCEL PAY DAN RICHARDS FOR SEXUALLY ATTACKING WANDA DEARTH.
300 shares today , zero yesterday . Thats DILUTION , really ?
If CHOI SAYS CCEL IS DILUTING THEN CCEL IS DILUTING. FACTS CANT BE DISPUTED. THANK YOU CHOI !
ALERT , ALERT EXCESSIVE DILUTION TODAY 300 shares traded ,yesterday zero shares , thats dilution ? At least he didn't hire his wife as a consultant or start a frozen Ice Cream Cake company on the side and make CCEL its biggest customer . Should be an interesting contest .
Yes I notice all the dilution , wait a minute how do you have dilution with no volume ?
I'm not surprised by this recent turn of events...
So why is CCEL DILUTING. I READ THAT
Did you hear that or did you read it somewhere ?
KEEP WASTING MONEY CCEL. I heard Dan Richards wasn't Paid his two $200,000 a year salary this year. Is this what he is Worth for Sexually Attacking Wanda Dearth or is he Worth more! STAY TUNED LMAO = Another Proxy OUT =
Additional Proxy Soliciting Materials - Non-Management (definitive) (DFAN14A)
Date :
06/26/2012 @ 11:42AM
Source :
Edgar (US Regulatory)
Stock :
Cryo-Cell Intl (CCEL)
Quote :
2.32 0.0 (0.00%) @ 5:01PM
- Additional Proxy Soliciting Materials - Non-Management (definitive) (DFAN14A)
Print
Alert
SCHEDULE 14A
(RULE 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
Filed by the Registrant ¨
Filed by a Party other than the Registrant ý
Check the appropriate box:
¨
Preliminary Proxy Statement
¨
Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
¨
Definitive Proxy Statement
¨
Definitive Additional Materials
ý
Soliciting Material Pursuant to §240.14a-12
CRYO-CELL INTERNATIONAL, INC.
(Name of Registrant as Specified in Its Charter)
Ki Yong Choi
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
Payment of Filing Fee (Check the appropriate box):
ý No fee required.
¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
1.
Title of each class of securities to which transaction applies:
2.
Aggregate number of securities to which transaction applies:
3.
Per unit price or other underlying value of transaction computed pursuant to Exchange Act
Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
4.
Proposed maximum aggregate value of transaction:
5.
Total fee paid:
¨ Fee paid previously with preliminary materials:
¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.
1.
Amount previously paid:
2.
Form, Schedule or Registration Statement No.:
3.
Filing Party:
4.
Date Filed:
Take Action to Save Cryo-Cell from Further Enriching Co-CEOs
VOTE THE GOLD PROXY CARD
STOCK OPTION POOL AUTHORIZED BY THE BOARD, IF FULLY ISSUED, WOULD DILUTE CURRENT STOCKHOLDER OWNERSHIP BY APPROXIMATELY 22%
San Francisco, CA. - June 26, 2012 /PRNewswire/-- Ki Yong Choi, who owns 2,186,568 shares of common stock of Cryo-Cell International, Inc. (OTCBB: CCEL), or approximately 19.6% of the company's outstanding shares, today issued the following letter to stockholders of Cryo-Cell.
ELECT A BOARD THAT IS COMMITTED TO ACTING IN THE BEST INTERESTS OF ALL STOCKHOLDERS
THE CURRENT BOARD APPROVED WHAT I BELIEVE TO BE EGREGIOUSLY COSTLY EMPLOYMENT CONTRACTS, EXCESSIVE STOCKHOLDER DILUTION AND SQUANDERING OF CASH. I DO NOT BELIEVE THESE ACTIONS SHOW REGARD FOR STOCKHOLDER VALUE.
Dear Fellow Cryo-Cell Stockholder:
I have launched a proxy contest to elect a slate of Board members to chart a new direction for the company. I have been involved with Cryo-Cell for over six years and I am the company’s largest stockholder. I have launched this contest because I believe the co-CEOs and the current members of the Board are mismanaging the company by, among other things, granting to the co-CEOs lavish compensation and stock incentives.
Vote the Gold Proxy Card to Change this Pattern
Brothers David Portnoy and Mark Portnoy conducted a proxy contest starting approximately one year ago. After winning the contest and taking control of Cryo-Cell near the end of August 2011, the newly-elected Board gave the Portnoys the co-CEO title, salaries that I believe are exorbitant, 600,000 stock options with no performance related vesting criteria, 600,000 more performance related stock options for next fiscal year and substantial change in control severance packages. The Board also reimbursed the Portnoy Group for litigation costs incurred by David Portnoy, even though a judge had denied his request for reimbursement.
These benefits have been awarded, despite what I believe is mismanagement of the company and deteriorating financial results. Find below a timeline of benefits and compensation awarded to the Portnoys (or Portnoy Group) by the Board.
August 2011 – Portnoy brothers appointed co-CEOs, at combined salaries in excess of the salary of the prior CEO. The Board appointed the Portnoy brothers as co-CEOs and gave them a combined salary that exceeded the previous CEO’s salary by more than $50,000 1 despite the fact their proxy statement stated they would “reduce executive cash compensation”.
August 2011 – 200,000 options granted immediately to the co-CEOs. The Board granted to each of the brother co-CEOs 100,000 options 2 . There were no vesting related performance criteria associated with these grants and they vest over two years with one third of the options vesting on the date of grant.
August 2011 – Cryo-Cell repaid to the Portnoy Group costs related to the litigation filed by David Portnoy in 2007 . The Board approved payment to the Portnoy Group for expenses related to David Portnoy’s proxy contest litigation in 2007, even though a judge had denied his request for reimbursement. 3
December 2011 - New stock option pool of 1,500,000 shares . Fresh off a large stock option grant the brother co-CEOs and the Board created the 2012 Equity Incentive Plan to reserve 1,500,000 shares for additional grants. 4
December 2011 - 3 months on the job = 400,000 more options unrelated to performance . The Board granted the brother co-CEOs a total of 400,000 additional options priced at $1.72 per share that vest over two years 5 . There were no performance related vesting criteria associated with these grants.
December 2011 - 600,000 performance-related options for the brother co-CEOs . The Board approved an additional 600,000 options for next fiscal year for the brother co-CEOs 6 . I believe the performance related vesting criteria of these grants are easily achievable and not necessarily related to the company’s operating performance.
December 2011 – Liberal change in control provision. Not only do I believe that the severance benefits are exorbitant, but the brother co-CEOs can collect them not only if there is a change in control due to a new Board, but also if someone simply submits a competing proxy solicitation. Should there be a change in control prior to December 1, 2012, 600,000 options automatically vest and the brother co-CEOs get a severance package of $850,000. If the change in control happens after October 31, 2013, the 600,000 performance-related options are granted and automatically vest.
December 2011 –Performance criteria for co-CEO bonuses I believe are easily achievable . The Board set three criteria that would allow the brother co-CEOs to collect 100% of their $425,000 cash salary bonus 7 . With 2.3 million shares remaining in the company’s share repurchase plan, I believe that further share repurchases will help the brother co-CEOs achieve at least two of their performance goals; the third performance goal remains a mystery. Unfortunately for Cryo-Cell stockholders, repurchasing shares drains the company’s cash reserves and does not improve the operating performance of the company.
A summary of the vesting criteria is as follows:
·
Criteria 1 - Diluted revenue per share of $1.75 . I believe the management team can reach this goal by keeping revenue flat and repurchasing shares 8 .
·
Criteria 2 - Stock price of $3.75 – Cryo-Cell stock currently trades about 5,000 shares per day – if the company repurchases up to 2.3 million shares, the stock price will likely increase.
·
Criteria 3 – Unstated . In the company’s SEC filing, the Board stated the third criteria “consists of subjective performance, as determined in the sole discretion of the Committee after consultation with the Executive .” Based on the Board’s generosity to the brother co-CEOs to this point, I believe this criterion will only favor the brother co-CEOs, as all of the other activities stated above do.
May 2012 - All options in the 2012 Equity Incentive Plan have been granted so Board reserves one million more. Having granted all of the 1,500,000 shares included in the 2012 Equity Incentive Plan within in six months, the Board added 1,000,000 more shares to the Plan, which now totals 2,500,000 shares 9 . This can result in more than 22% dilution to the stockholder base if fully issued . This option pool expansion comes directly after the company reported significant losses in its February 2012 fiscal quarter.
I BELIEVE THE SHARE BUY BACK PROGRAM IS NOT IN THE BEST INTERESTS OF THE COMPANY.
I DO NOT BELIEVE THE ACTIONS OF THIS BOARD SHOW THEY ARE LOOKING OUT FOR ALL STOCKHOLDERS.
To recap: in six months the Board gave the Portnoys the co-CEO title, what I believe are exorbitant salaries, 600,000 options with no performance related vesting criteria, 600,000 more performance-related options for next fiscal year, and substantial change in control severance packages. The Board also reimbursed the Portnoy Group for litigation costs that had been denied to David Portnoy in his 2007 legal action. I cannot think of one way these actions benefit stockholders.
I have carefully chosen what I believe to be a well-rounded group of independent Director nominees with whom I have no existing business relationship. I believe that each Director brings important industry expertise, contacts and the kind of specialized experience that I believe is required to drive stockholder value for Cryo-Cell. As a team, we are completely dedicated to turning around Cryo-Cell.
VOTE THE GOLD PROXY CARD TO MAKE A DIFFERENCE IN CRYO-CELL’S FUTURE
Time is short. No matter how many or how few shares you own, it is important that you return the GOLD proxy card and vote in favor of electing us to represent you in the boardroom. You should WAIT TO RECIEVE the definitive proxy materials and the GOLD proxy card that will be mailed to you. You SHOULD NOT RETURN THE WHITE PROXY CARD or any other proxy card furnished to you on behalf of Cryo-Cell.
What should you do now? Once you receive a GOLD proxy card, vote to elect directors who will work for all of Cryo-Cell’s stockholders by signing and returning the GOLD proxy card .
If you have already returned a proxy card, you have every right to change your vote by signing and returning a later-dated GOLD proxy card once it is provided to you.
As the largest stockholder and a person who cares about Cryo-Cell, I vow to work tirelessly to get the company back on track. I thank you and look forward to your support.
Ki Yong Choi
Investor Contact:
Alliance Advisors LLC.
Call Toll Free: (877) 777-2338;
Banks and Brokers Call Collect: (973) 873-7700.
--------------------------------------------------------------------------------
1 SEC form 10-K filed 2-28-12 and SEC form 8-K filed 12-7-2011.
2 SEC form 10-Q filed 10-17-2011, p. 15. Options granted August 31, 2011.
3 SEC form 10-Q filed 10-17-2011, p. 20. Payment approved August 31, 2011. Also see Portnoy v. Cryo-Cell International, Inc. decided by the Delaware Court of Chancery on January 15, 2008.
4 SEC form 8K filed 12-7-2011. 2012 Equity Incentive Plan approved by Board 12-1-2011.
5 SEC form 8K filed 12-7-2011. Employment agreement that granted options approved by Board 12-1-2011.
6 SEC form 8K filed 12-7-2011. Employment agreement that granted options approved by Board 12-1-2011.
7 SEC form 8K filed 12-7-2011. Employment agreements for David and Mark Portnoy, Section 3.b. approved by Board 12-1-2011.
8 Per SEC form 10-Q filed 4-16-2012 the company had 11,488,980 diluted shares as of February 29, 2012. With revenue of $17.9 million in the last fiscal year and 11.2 million shares outstanding, if management directs the company to repurchase 1.26 million shares and holds revenue flat, the company will achieve the diluted revenue per share target of $1.75.
9 SEC form DEFC14A filed June 21, 2012, p. 26.
In connection with his intended proxy solicitation, on June 25, 2012 Ki Yong Choi filed a definitive proxy statement with the Securities and Exchange Commission (the “SEC”) to solicit stockholders of Cryo-Cell International, Inc. MR. CHOI STRONGLY ADVISES ALL STOCKHOLDERS OF CRYO-CELL INTERNATIONAL, INC. TO READ THE PROXY STATEMENT BECAUSE IT CONTAINS IMPORTANT INFORMATION, INCLUDING INFORMATION RELATING TO THE PARTICIPANTS IN SUCH PROXY SOLICITATION. THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS ARE AVAILABLE AT NO CHARGE ON THE SEC’S WEBSITE AT HTTP://WWW.SEC.GOV.
PARTICIPANT INFORMATION
In accordance with Rule 14a-12(a)(1)(i) under the Securities Exchange Act of 1934, as amended, the following persons are anticipated to be, or may be deemed to be, participants in any such proxy solicitation: Ki Yong Choi, Gary Weinhouse, Michael W. Cho, Warren Hoeffler, Michael D. Coffee and Ajay Badlani. Certain of these persons hold direct or indirect interests in Cryo-Cell International, Inc. as follows: Mr. Choi holds of record or beneficially a total of 2,186,568 shares of Cryo-Cell International, Inc.’s common stock and Dr. Michael W. Cho is the record holder of 14,166 shares of Cryo-Cell International, Inc.’s common stock. Messrs. Choi, Weinhouse, Cho, Hoeffler, Coffee and Badlani each have an interest in being nominated and elected as a director of Cryo-Cell International, Inc. Information about the participants has been set forth in the definitive proxy statement filed by Mr. Choi with the SEC on June 25, 2012.
Yup everyone is running for the exit , not .
EXCESSIVE STOCKHOLDER DILUTION ELECT A BOARD THAT IS COMMITTED TO ACTING IN THE BEST INTERESTS OF ALL STOCKHOLDERS
THE CURRENT BOARD APPROVED WHAT I BELIEVE TO BE EGREGIOUSLY COSTLY EMPLOYMENT CONTRACTS, EXCESSIVE STOCKHOLDER DILUTION AND SQUANDERING OF CASH. I DO NOT BELIEVE THESE ACTIONS SHOW REGARD FOR STOCKHOLDER VALUE.
Typical CCEL CRAP!
CCELs EXCESSIVE DILUTION. THATS JUST GREAT!
A rarity in a world of greed. Kudos to Choi!
That's what I mean, a whistle-blower who has the #'s to call someone a$$ out lol, love it.
Amusing, but the #'s back up his claim - no denying that.
I actually found it quite amusing lol
I wish Choi would tell us how he REALLY felt.......
What kind of PR is that lol?
http://ih.advfn.com/p.php?pid=nmona&article=52893135&symbol=CCEL
So, what happens if he sells?
The POOR BROTHERS ARE GOING HAVE TO EXPECT THAT IF CHOI DOESN'T GET HIS WAY HE WILL SELL ALL HIS SHARES. GOOD IT SERVES THE POOR BROTHERS RIGHT. S
Followers
|
28
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
5497
|
Created
|
05/26/05
|
Type
|
Free
|
Moderators |
Cryo-Cell International, Inc.(CCEL)
Company Information:
700 Brooker Creek Blvd.
Suite 1800
Oldsmar, FL 34677
Phone: 813-749-2100
Toll Free: 800-786-7235
Fax: 813-855-4745
Cryo-Cell International, Inc. was established in 1989 with a primary focus on the cryopreservation of umbilical cord (U-Cord®) stem cells for family use. Since our inception, we have been committed to the development and adoption of industry best practices and technologies.
Cord blood stem cell transplants have already changed-and saved-thousands of lives around the world. What's more, science is honing in on other miraculous uses for these precious cells, potentially impacting countless numbers of lives in the future.
Ever-committed to the highest quality, we treat every specimen of umbilical cord blood as if it were our own. Every sample we receive, process and preserve represents a potentially life-saving treatment for a child. This concept fuels our resolve to only hire the most talented candidates, develop and implement the most effective training and continuously fine-tune our processes. From the design and specifications of our collection kit, to the choice of each supplier, our dedication to quality remains unwavering.
Cryo-Cell International, Inc. ("the Company" or "Cryo-Cell") operates in one reportable segment and is principally engaged in cellular processing and cryogenic storage, with a current focus on the collection and preservation of umbilical cord (U-Cord®) blood stem cells for family use. The Company, in combination with its global affiliates currently stores over 200,000 cord blood specimens worldwide for the exclusive benefit of newborn babies and possibly other members of their families. The Company is one of the world's largest and most established private family cord blood stem cell banks in terms of the number of specimens preserved. Its headquarters facility in Oldsmar, Florida handles all aspects of its U.S.-based business operations, including the processing and storage of specimens. The specimens are stored in commercially available cryogenic storage units at the Company's technologically and operationally advanced facility in Oldsmar, Florida.
In recent years, the Company has expanded its research and development ("R&D") activities to develop technologies related to stem cells other than umbilical cord blood stem cells such as fetal and maternal stem cells harvested from the placenta. During 2006, the Company discovered novel technology related to menstrual stem cells. In November 2007, the Company announced the launch of its C'elleSM service related to this patent-pending technology, and the Company continues to focus its current research and development activities principally on the C'elle service and related new menstrual stem cell technologies. The Company is actively marketing the C'elle service which is available both through a bundled offer with the Company's U-Cord service and on a stand-alone basis.
Employees: At November 30, 2009, there are 48 full-time employees and 1 part-time employee on the staff of the Company. Additional employees and staff will be hired on an "as needed" basis. The Company believes its relationship with its employees is good. None of our employees are members of any labor union, and we are not a party to any collective bargaining agreement.
Here's a video which shows the importance of saving cord blood: http://video.foxnews.com/11461523/cord-blood-miracle/?category_id=949437d0db05ed5f5b9954dc049d70b0c12f2749
Cryo-Cell International, Inc. holds an equity position in Saneron CCEL Therapeutics (Saneron), a University of South Florida spin-out biotechnology company. Saneron is committed to advancing research using readily available, non-controversial cord blood stem cells. Saneron's research focus is to actively seek new cellular therapy discoveries for treatment of and intervention in devastating, life-threatening illness and conditions such as heart attack, Alzheimer's disease, stroke, and spinal cord injury.
For more information, visit Saneron's Web site: www.saneron-ccel.com
Cryo-Cell is International
In order to provide the Cryo-Cell U-Cord® Stem Cell Preservation Service abroad, we are establishing affiliates in countries around the world. Currently, we have affiliates in the following areas:
See page 15 of SEC filing for further details: http://www.sec.gov/Archives/edgar/data/862692/000119312511189394/d10q.htm
C'elle distributor opportunity for doctors that specialize in female issues. See video:
http://www.celle.com/distributorVideo.aspx#
_______________________________________________________________________________________________________________________________________________________
Cryo-Cell International, Inc. has been a publicly traded company since 1991. Governed by the Securities & Exchange Commission, our common stock trades under the OTC Bulletin Board symbol CCEL. We specialize in U-Cord® stem cell preservation for family use.
Investor Relations: http://www.cryo-cell.com/investor_relations/
Investor Information: To request Cryo-Cell's Investor's Information Kit, or to receive Cryo-Cell's press releases via email, please fill out this form: http://www.cryo-cell.com/investor_relations/investor_info.asp
Section 16 Filings: All Insiders Annual Reports Quarterly & Other Reports Stock Quote Fundamentals News Chart Real-Time Filings
_______________________________________________________________________________________________________________________________________________________
Recent News:
http://www.cryo-cell.com/investor_relations/
http://finance.yahoo.com/q/h?s=CCEL.OB+Headlines
http://www.nasdaq.com/aspxcontent/newsheadlines.aspx?symbol=CCEL&selected=CCEL&SourceCode=PMZ
Filings:
Transfer Agent:
Continental Stock Transfer & Trust Company
17 Battery Place, 8th Floor
New York 10004
__________________________________________________________________________________________________________________________
Share Structure:
See SEC filing link for latest share structure info.
______________________________________
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn't a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |